Children with achondroplasia who are treated for the condition currently face daily or weekly injections, a demand that falls on families for years. A phase 3 trial of an oral alternative has now drawn an unusually direct endorsement from a specialist writing in the New England Journal of Medicine.
Dr. Isidro B. Salusky of UCLA Health described the trial results as "a potentially giant step forward" in an editorial published in the journal on September 2. The full commentary appears among the journal's featured content. Salusky is a distinguished professor of pediatrics at the David Geffen School of Medicine at UCLA and chief of pediatric nephrology. The editorial was co-written with Dr. Harald Jueppner of Massachusetts General Hospital.
The framing matters. This is a signed commentary by two named physicians, not a guideline, a regulatory decision, or a consensus statement from a medical society. Readers should weigh it as informed expert opinion.
An Opinion Piece Is the News, and the Trial Is Older Than It Looks
The trial itself was published in June. What appeared this month is the editorial assessing it, which is why the story is surfacing now.
That distinction is worth stating because coverage of journal editorials can make older findings look like fresh discoveries. Nothing new was measured. What is new is that two specialists in pediatric bone and mineral disorders put their names to an assessment of what the results mean.
Achondroplasia is a skeletal condition characterized by disproportionate short stature. It is the most common form of short-limbed dwarfism, and it can bring medical, functional, and psychosocial challenges across a lifetime.
Treatment decisions in this community are also contested. Some families and advocates question whether medical intervention in a child's growth is desirable at all, viewing the condition as a difference rather than a disease to be corrected. Others prioritize reducing the orthopedic and respiratory complications that can accompany it. An editorial endorsement does not resolve that debate, and this article does not attempt to.
The Trial Behind the Commentary
The study assessed once-daily oral infigratinib in 114 randomly assigned children with achondroplasia aged 3 to 17. Seventy-five received the drug, and 39 received a placebo.
After 52 weeks, treatment produced a significantly greater increase from baseline growth than placebo. That is the headline finding, and it comes from a randomized placebo-controlled design, which is the strongest common study type for this kind of question.
Salusky wrote that the study offers a promising approach for improving bone growth over time in children with the condition. He also wrote that beyond addressing an unmet need, the trial highlights the value of international collaborations for studying treatments in children with rare genetic bone disorders.
The comparison group received placebo rather than an active treatment, which means the trial establishes that the drug outperforms nothing. It does not establish how it compares with the injectable therapy families are currently offered.
Growth over one year is a measurable outcome, but it is not the same as a functional or health outcome. The trial does not establish whether treated children experience fewer of the medical complications associated with the condition, such as the spinal and joint problems associated with the condition, or whether adult height differs meaningfully. Those questions require far longer follow-up.
The Case for Swallowing Rather Than Injecting
The argument for an oral drug is not primarily about efficacy. It is about whether families can sustain treatment at all.
Existing drug treatment requires daily or weekly injections. For a young child, that means a recurring event that a parent administers, with the resistance and distress that come with it. Adherence over years of childhood is a real clinical problem, not a minor inconvenience.
It also shapes household logistics. Injectable therapy involves refrigerated storage, supply deliveries, sharps disposal, and a caregiver confident enough to give a dose correctly on schedule. A tablet removes most of that burden, which is a practical argument that has little to do with how well either drug works.
Salusky argued that the effect of medication is most pronounced when started early, and that oral availability is "particularly suitable for treating infants, who are most likely to benefit."
That claim deserves a clear caveat. The trial enrolled children aged 3 to 17. It did not include infants. Salusky is describing a logical advantage of an oral formulation, not reporting evidence that the drug works in babies. No infant data exist from this study.
Questions the Editorial Does Not Resolve
Several things remain open, and families should hold them in view before drawing conclusions from a favorable commentary.
The trial ran 52 weeks. Long-term safety in growing children, particularly for a drug in this class, has not been established over the timeframe that matters for a childhood condition. Whether growth gains persist, plateau, or reverse after treatment stops is unknown from these data.
Regulatory status is a separate matter from journal publication. An editorial in a leading journal does not mean a treatment is approved, available, or covered by insurance, and readers should not assume they can request it from a pediatrician.
Cost and access questions have not been addressed publicly. Treatments for rare pediatric conditions typically carry high prices and require prior authorization, and families should expect that process rather than assume coverage.
Parents of a child with achondroplasia who want to discuss options should raise them with a pediatric endocrinologist or a specialist in skeletal dysplasia, ask what evidence exists for the specific age of their child, and ask what outcomes beyond height have been measured. Families should not treat height gain as the only measure of whether an intervention is worthwhile, and no one should start or seek treatment on the basis of a news report.
Key Questions Answered
What is the news here? An editorial in the New England Journal of Medicine assessing a phase 3 trial of oral infigratinib in children with achondroplasia. The trial itself was published in June.
Who wrote the editorial? Dr. Isidro B. Salusky of UCLA Health and Dr. Harald Jueppner of Massachusetts General Hospital. It is a signed commentary, not a guideline or consensus statement.
What did the trial find? In 114 children aged 3 to 17, once-daily oral infigratinib for 52 weeks produced a significantly greater increase from baseline growth than placebo. Seventy-five children received the drug and 39 received placebo.
Why does an oral drug matter? Current drug treatment requires daily or weekly injections, which is difficult to sustain in young children over years.
Was the drug tested in infants? No. The trial enrolled children aged 3 to 17. The editorial's comment about suitability for infants describes a potential advantage of an oral formulation, not evidence from this study.
Is the treatment available now? Publication in a journal is not the same as regulatory approval, availability or insurance coverage. Families should discuss options with a pediatric specialist.
What remains unknown? Long-term safety, whether growth gains persist, and whether treatment reduces the medical complications associated with the condition. The trial measured 52 weeks of growth.
